Shane Kovacs

Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases

Operates as a shell company with no operations

Operates as a drug discovery and development company

NBF offers the following investment vehicles for individual investors: bonds, savings bonds, retirement savings bonds, foreign currency bonds, strip bonds, Treasury bills, commercial paper, investment certificates and term deposits, MBS, preferred shares, common shares, Canadian mutual funds, US mutual funds, international mutual funds and options and derivative products.

Functions as a College/University

Functions as a College/University

Provides brokerage services

Provides investment advice

PTC Therapeutics International Ltd. is an Irish biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare diseases with high unmet medical needs. The company is based in DU. The company addresses the root causes of serious genetic, metabolic, and neurological conditions through approaches such as RNA splicing modulation and targeting oxidative stress and inflammation pathways, particularly in central nervous system disorders. Its therapeutic portfolio and pipeline include treatments for rare diseases such as phenylketonuria (PKU), aromatic l-amino acid decarboxylase (AADC) deficiency, Duchenne muscular dystrophy (DMD), hereditary transthyretin amyloidosis (hATTR), familial partial lipodystrophy (FPL), spinal muscular atrophy (SMA), and Friedreich’s ataxia. PTC collaborates with partners to bring treatments to market and supports patients, caregivers, and healthcare providers through educational programs and personalized assistance. The company conducts clinical trials and investigator-initiated studies, maintains dedicated patient engagement teams, and emphasizes corporate responsibility, compliance, and transparency with investors.